Lab
Harbor Medical Associates, INC.
Harbor Medical Associates, INC. was paid $421K by Medicaid between Jan 2018 and Nov 2024, across 83 billing codes. Its largest line is 84443, Thyroid stimulating hormone (TSH) — 10% of everything it billed.
33Billing provider infoHARBOR MEDICAL ASSOCIATES, INC.
SOUTH WEYMOUTH, MA 02190
SOUTH WEYMOUTH, MA 02190
33aNPI1396942926assigned 06/28/2007
33bProvider typeClinical Medical Laboratory
28Total paid$421K
24GClaims140,042
24DCodes billed83
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Massachusetts
Rank by total paid#33 of 63
Median peer was paid$473K
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 21,695 | $45K | |
| 2019 | 20,307 | $61K | |
| 2020 | 20,151 | $62K | |
| 2021 | 24,411 | $103K | |
| 2022 | 24,658 | $99K | |
| 2023 | 17,429 | $40K | |
| 2024incomplete | 11,391 | $12K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 84443 | Thyroid stimulating hormone (TSH) | 10% | 7,182 | 7,092 | $43K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 9.3% | 3,932 | 3,903 | $39K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 7.6% | 16,628 | 14,347 | $32K |
| ATP14 | 6.4% | 7,674 | 7,058 | $27K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 4.7% | 1,246 | 1,242 | $20K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 4.6% | 202 | 199 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | 4.5% | 6,236 | 6,196 | $19K |
| ATP17 | 3.3% | 3,762 | 3,750 | $14K | |
| 82607 | 3.2% | 2,444 | 2,435 | $13K | |
| 82728 | 2.9% | 2,611 | 2,556 | $12K | |
| 85027 | 2.9% | 5,191 | 5,023 | $12K | |
| 86803 | 2.7% | 1,424 | 1,421 | $11K |
71 more codes
| 80050 | General health panel | 2.6% | 675 | $11K |
| ATP08 | 2.4% | 4,650 | $10K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.3% | 353 | $10K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.3% | 353 | $10K |
| ATP15 | 2.0% | 2,023 | $8K | |
| 86141 | 1.9% | 1,527 | $8K | |
| 84439 | 1.8% | 2,198 | $8K | |
| 83970 | 1.7% | 611 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.7% | 2,602 | $7K |
| 83550 | 1.6% | 2,395 | $7K | |
| 83540 | 1.4% | 2,687 | $6K | |
| 83721 | 1.2% | 1,493 | $5K | |
| 83735 | 1.1% | 2,265 | $5K | |
| ATP03 | 1.1% | 1,052 | $4K | |
| 82570 | <1% | 2,669 | $3K | |
| 83880 | <1% | 529 | $3K | |
| ATP11 | <1% | 987 | $3K | |
| 85610 | <1% | 3,270 | $3K | |
| 82746 | <1% | 480 | $3K | |
| 82043 | <1% | 2,073 | $3K | |
| 87660 | <1% | 195 | $3K | |
| 87480 | <1% | 187 | $3K | |
| 83690 | <1% | 875 | $2K | |
| 84702 | <1% | 192 | $2K | |
| 87510 | <1% | 169 | $2K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 114 | $2K |
| 81001 | <1% | 2,193 | $2K | |
| 80053 | Comprehensive metabolic panel | <1% | 14,131 | $2K |
| 85652 | <1% | 1,361 | $1K | |
| 80061 | Lipid panel | <1% | 7,887 | $1K |
| 81003 | <1% | 1,256 | $1K | |
| 86618 | <1% | 105 | $976.91 | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $975.00 |
| 86780 | <1% | 85 | $819.96 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 29 | $813.54 |
| 87340 | <1% | 119 | $748.64 | |
| 87077 | <1% | 284 | $723.54 | |
| 84146 | <1% | 49 | $654.06 | |
| 87186 | <1% | 246 | $618.14 | |
| 82378 | <1% | 53 | $558.20 | |
| 82784 | <1% | 115 | $489.54 | |
| 80164 | <1% | 264 | $457.54 | |
| 86038 | <1% | 67 | $457.08 | |
| 87081 | <1% | 166 | $440.40 | |
| 86334 | <1% | 61 | $402.20 | |
| ATP18 | <1% | 81 | $330.15 | |
| 84165 | <1% | 41 | $317.64 | |
| 83001 | <1% | 25 | $315.89 | |
| 84100 | <1% | 1,811 | $310.21 | |
| 84436 | <1% | 109 | $297.75 | |
| 84480 | <1% | 38 | $271.74 | |
| 82150 | <1% | 81 | $234.32 | |
| 84153 | <1% | 12 | $145.98 | |
| ATP07 | <1% | 30 | $136.80 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 412 | $113.70 |
| 85651 | <1% | 97 | $113.15 | |
| 83516 | <1% | 13 | $94.48 | |
| 83615 | <1% | 129 | $91.99 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,381 | $90.84 |
| 84550 | <1% | 336 | $81.60 | |
| 86140 | <1% | 31 | $64.08 | |
| 85007 | <1% | 68 | $63.72 | |
| 82550 | <1% | 69 | $61.71 | |
| 81015 | <1% | 44 | $56.52 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,306 | $26.65 |
| 84156 | <1% | 25 | $22.68 | |
| 82565 | <1% | 24 | $4.68 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 0% | 370 | $0.00 |
| 99000 | 0% | 389 | $0.00 | |
| 80076 | 0% | 1,466 | $0.00 | |
| 82248 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRAPE, PETER (CHIEF)
Parent organizationHARBOR MEDICAL ASSOCIATES, INC.
| Provider | Location | Paid |
|---|---|---|
| Harbor Medical Associates, INC. | South Weymouth, MA | $191K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.